MedTrace Logo

Phase II Study of RC1416 Injection in COPD

NCT07402551 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-04-17

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of RC1416 injection in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Conditions

  • Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

RC1416

There are two doses in this part. Each subjects will receive the drug by subcutaneous injection.

DRUG

RC1416 Placebo

Each subjects will receive the placebo by subcutaneous injection.

Sponsors & Collaborators

  • Nanjing RegeneCore Biotech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-06
Primary Completion
2028-05-31
Completion
2028-08-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07402551 on ClinicalTrials.gov